Statins as potential treatment for cholesterol gallstones: an attempt to understand the underlying mechanism of actions

Bibliography

• Petroni ML, Jazrawi RP, Pazzi P, Risk factors for the development of gallstone recurrence following medical dissolution. The British-Italian Gallstone Study Group. Eur J Gastroenterol Hepatol 2000;12:695-700
   PubMed Web of Science ®Google Scholar
• Shaffer EA. Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century? Curr Gastroenterol Rep 2005;7:132-40
   PubMedGoogle Scholar
• Heaton KW. Review article: epidemiology of gall-bladder disease – role of intestinal transit. Aliment Pharmacol Ther 2000;14(Suppl 2):9-13
   Google Scholar
• Heaton KW. Cholesterol-rich gallstones. Mol Aspects Med 1987;9:89-96
   PubMed Web of Science ®Google Scholar
• Diehl AK. Epidemiology and natural history of gallstone disease. Gastroenterol Clin North Am 1991;20:1-19
   PubMed Web of Science ®Google Scholar
• Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Prospective study of abdominal adiposity and gallstone disease in US men. Am J Clin Nutr 2004;80:38-44
   PubMed Web of Science ®Google Scholar
• Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Central adiposity, regional fat distribution, and the risk of cholecystectomy in women. Gut 2006;55:708-14
   PubMed Web of Science ®Google Scholar
• Leitzmann MF, Giovannucci EL, Rimm EB, The relation of physical activity to risk for symptomatic gallstone disease in men. Ann Intern Med 1998;128:417-25
   PubMed Web of Science ®Google Scholar
• Festi D, Dormi A, Capodicasa S, Incidence of gallstone disease in Italy: results from a multicenter, population-based Italian study (the MICOL project). World J Gastroenterol 2008;14:5282-9
   PubMed Web of Science ®Google Scholar
• Biddinger SB, Haas JT, Yu BB, Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med 2008;14:778-82
   PubMed Web of Science ®Google Scholar
• Wang HH, Portincasa P, Afdhal NH, Wang DQ. Lith genes and genetic analysis of cholesterol gallstone formation. Gastroenterol Clin North Am 2010;39:185- viii
   PubMed Web of Science ®Google Scholar
• Wang HH, Portincasa P, Wang DQ. Molecular pathophysiology and physical chemistry of cholesterol gallstones. Front Biosci 2008;13:401-23
   PubMed Web of Science ®Google Scholar
• Shaffer EA. Gallstone disease: epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol 2006;20:981-96
   PubMed Web of Science ®Google Scholar
• Ruhl CE, Everhart JE. Gallstone disease is associated with increased mortality in the United States. Gastroenterology 2010;2:508-16
   Google Scholar
• Mendez-Sanchez N, Bahena-Aponte J, Chavez-Tapia NC, Strong association between gallstones and cardiovascular disease. Am J Gastroenterol 2005;100:827-30
   PubMed Web of Science ®Google Scholar
• Mendez-Sanchez N, Zamora-Valdes D, Flores-Rangel JA, Gallstones are associated with carotid atherosclerosis. Liver Int 2008;28:402-6
   PubMed Web of Science ®Google Scholar
• Bortnichak EA, Freeman DH Jr, Ostfeld AM, The association between cholesterol cholelithiasis and coronary heart disease in Framingham, Massachusetts. Am J Epidemiol 1985;121:19-30
   PubMedGoogle Scholar
• Sandler RS, Everhart JE, Donowitz M, The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:1500-11
   PubMed Web of Science ®Google Scholar
• Portincasa P, Moschetta A, Petruzzelli M, Gallstone disease: symptoms and diagnosis of gallbladder stones. Best Pract Res Clin Gastroenterol 2006;20:1017-29
   PubMed Web of Science ®Google Scholar
• Ahmed MH. Ezetimbe as potential treatment for cholesterol gallstones: the need for clinical trials. World J Gastroenterol 2010;16:1555-7
   PubMed Web of Science ®Google Scholar
• Marschall HU, Einarsson C. Gallstone disease. J Intern Med 2007;261:529-42
   PubMed Web of Science ®Google Scholar
• Ahmed MH, Osman MM, Alokail MS. Statins and breast cancer: a smoking gun or guilt by association? Expert Opin Drug Saf 2006;5:599-601
   PubMed Web of Science ®Google Scholar
• Wang HR, Li JJ, Huang CX, Jiang H. Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. Clin Chim Acta 2005;353:53-60
   PubMed Web of Science ®Google Scholar
• Romano M, Diomede L, Sironi M, Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000;80:1095-100
   PubMed Web of Science ®Google Scholar
• Pasterkamp G, van Lammeren GW. Pleiotropic effects of statins in atherosclerotic disease. Expert Rev Cardiovasc Ther 2010;8:1235-7
   PubMedGoogle Scholar
• Gurll N, DenBesten L. Animal models of human cholesterol gallstone disease: a review. Lab Anim Sci 1978;28:428-32
   Google Scholar
• Brenneman DE, Connor WE, Forker EL, DenBesten L. The formation of abnormal bile and cholesterol gallstones from dietary cholesterol in the prairie dog. J Clin Invest 1972;51:1495-503
   PubMed Web of Science ®Google Scholar
• Holzbach RT. Animal models of cholesterol gallstone disease. Hepatology 1984;4:191-198S
   PubMed Web of Science ®Google Scholar
• Saunders KD, Cates JA, Abedin MZ, Lovastatin inhibits gallstone formation in the cholesterol-fed prairie dog. Ann Surg 1991;2:149-54
   Google Scholar
• Abedin MZ, Narins SC, Park EH, Lovastatin alters biliary lipid composition and dissolves gallstones: a long-term study in prairie dogs. Dig Dis Sci 2002;47:2192-210
   PubMed Web of Science ®Google Scholar
• Davis KG, Wertin TM, Schriver JP. The use of simvastatin for the prevention of gallstones in the lithogenic prairie dog model. Obes Surg 2003;13:865-8
   PubMed Web of Science ®Google Scholar
• Tazuma S, Hatsushika S, Aihara N, Inhibitory effects of pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in prairie dogs. Digestion 1992;51:179-84
   PubMed Web of Science ®Google Scholar
• Saunders KD, Cates JA, Abedin MZ, Roslyn JJ. Lovastatin and gallstone dissolution: a preliminary study. Surgery 1993;113:28-35
   PubMedGoogle Scholar
• Erichsen R, Froslev T, Lash TL, Long-term statin use and the risk of gallstone disease: a population-based case-control study. Am J Epidemiol 2011;173:162-70
   PubMed Web of Science ®Google Scholar
• Bodmer M, Brauchli YB, Krahenbuhl S, Statin use and risk of gallstone disease followed by cholecystectomy. JAMA 2009;302:2001-7
   PubMed Web of Science ®Google Scholar
• Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Statin use and the risk of cholecystectomy in women. Gastroenterology 2009;136:1593-600
   PubMed Web of Science ®Google Scholar
• Merzon E, Weiss NS, Lustman AJ, Statin administration and risk of cholecystectomy: a population-based case-control study. Expert Opin Drug Saf 2010;9:539-43
   PubMed Web of Science ®Google Scholar
• Caroli-Bosc FX, Le Gall P, Pugliese P, Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Dig Dis Sci 2001;46:540-4
   PubMed Web of Science ®Google Scholar
• Sackmann M, Koelbl R, Pauletzki J, Simvastatin added to ursodeoxycholic acid does not enhance disappearance of gallstone fragments after shock wave therapy. Z Gastroenterol 1995;33:585-9
   Google Scholar
• Duane WC, Hunninghake DB, Freeman ML. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology 1988;8:1147-50
   PubMed Web of Science ®Google Scholar
• Logan GM, Duane WC. Lovastatin added to ursodeoxycholic acid further reduces biliary cholesterol saturation. Gastroenterology 1990;98:1572-6
   PubMedGoogle Scholar
• Nitsche R, Schlage J, Ramin V, Influence of the HMG-CoA-reductase inhibitor lovastatin on cholesterol saturation index and nucleation time of duodenal bile. Z Gastroenterol 1991;29:242-5
   Google Scholar
• Duane WC. Effects of lovastatin and dietary cholesterol on bile acid kinetics and bile lipid composition in healthy male subjects. J Lipid Res 1994;35:501-9
   Google Scholar
• Tazuma S, Kajiyama G, Mizuno T, A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy. J Clin Gastroenterol 1998;26:287-91
   PubMed Web of Science ®Google Scholar
• Hillebrant CG, Nyberg B, Gustafsson U, Effects of combined treatment with pravastatin and ursodeoxycholic acid on hepatic cholesterol metabolism. Eur J Clin Invest 2002;32:528-34
   PubMed Web of Science ®Google Scholar
• Hillebrant CG, Axelson M, Bjorkhem I, Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest 1998;28:324-8
   Google Scholar
• Smith JL, Roach PD, Wittenberg LN, Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones. J Gastroenterol Hepatol 2000;15:871-9
   PubMed Web of Science ®Google Scholar
• Chapman BA, Burt MJ, Chisholm RJ, Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor. Dig Dis Sci 1998;43:349-53
   PubMed Web of Science ®Google Scholar
• Vaishnavi C, Singh S, Kochhar R, C-reactive protein in patients with gallbladder and biliary tract diseases. Trop Gastroenterol 2004;25:73-5
   Google Scholar
• Maurer KJ, Carey MC, Fox JG. Roles of infection, inflammation, and the immune system in cholesterol gallstone formation. Gastroenterology 2009;136:425-40
   PubMed Web of Science ®Google Scholar
• Ahmed MH, Byrne CD. Metabolic syndrome, diabetes & CHD risk. In: Packard CJ, editor. The year in lipid disorders. Clinical Publishing; Oxford: 2007. p. 3-26
   Google Scholar
• Ahmed MH, Byrne CD. Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discov Today 2007;12:740-7
   PubMed Web of Science ®Google Scholar
• Ahmed MH, Abu EO, Byrne CD. Non-alcoholic fatty liver disease (NAFLD): new challenge for general practitioners and important burden for health authorities? Prim Care Diabetes 2010;3:129-37
   Google Scholar
• Caroli-Bosc FX, Le Gall P, Pugliese P, Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Dig Dis Sci 2001;46:540-4
   PubMed Web of Science ®Google Scholar
• Raedsch R, Plachky J, Wolf N, Simonis G. Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment. Eur J Drug Metab Pharmacokinet 1995;20:113-18
   Google Scholar
• Wilson IR, Hurrell MA, Pattinson NR, Chapman BA. The effect of simvastatin and bezafibrate on bile composition and gall-bladder emptying in female non-insulin-dependent diabetics. J Gastroenterol Hepatol 1994;9:447-51
   PubMed Web of Science ®Google Scholar
• Jonkers IJ, Smelt AH, Princen HM, Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia. J Nutr 2006;136:987-91
   PubMed Web of Science ®Google Scholar
• Jonkers IJ, Smelt AH, Ledeboer M, Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil. Gut 2003;52:109-15
   PubMed Web of Science ®Google Scholar
• Mendez-Sanchez N, Gonzalez V, Aguayo P, Fish oil (n-3) polyunsaturated fatty acids beneficially affect biliary cholesterol nucleation time in obese women losing weight. J Nutr 2001;131:2300-3
   PubMed Web of Science ®Google Scholar
• Magnuson TH, Lillemoe KD, High RC, Pitt HA. Dietary fish oil inhibits cholesterol monohydrate crystal nucleation and gallstone formation in the prairie dog. Surgery 1995;118:517-23
   Google Scholar
• Berr F, Holl J, Jungst D, Dietary N-3 polyunsaturated fatty acids decrease biliary cholesterol saturation in gallstone disease. Hepatology 1992;16:960-7
   Google Scholar
• Mathur A, Walker JJ, Al-Azzawi HH, Ezetimibe ameliorates cholecystosteatosis. Surgery 2007;142:228-33
   PubMed Web of Science ®Google Scholar
• Valasek MA, Repa JJ, Quan G, Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters. Am J Physiol Gastrointest Liver Physiol 2008;295:G813-22
   Google Scholar
• Zuniga S, Molina H, Azocar L, Ezetimibe prevents cholesterol gallstone formation in mice. Liver Int 2008;28:935-47
   PubMed Web of Science ®Google Scholar
• Wang HH, Portincasa P, Mendez-Sanchez N, Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology 2008;134:2101-10
   PubMed Web of Science ®Google Scholar
• Cannon CP, Giugliano RP, Blazing MA, Rationale and design of IMPROVE-IT (improved reduction of outcomes: vytorin efficacy international trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008;156:826-32
   PubMed Web of Science ®Google Scholar
• Holland RE, Rahman K, Morris AI, Effects of niacin on biliary lipid output in the rat. Biochem Pharmacol 1993;45:43-9
   Google Scholar
• Einarsson K, Ericsson S, Ewerth S, Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol 1991;40(Suppl 1):S53-8
   Google Scholar
• Gustafsson BE, Angelin B, Einarsson K, Gustafsson JA. Influence of cholestyramine on synthesis of cholesterol and bile acids in germfree rats. J Lipid Res 1978;19:972-7
   PubMed Web of Science ®Google Scholar
• Carrella M, Ericsson S, Del Piano C, Effect of cholestyramine treatment on biliary lipid secretion rates in normolipidaemic men. J Intern Med 1991;229:241-6
   Google Scholar
• Bertolotti M, Abate N, Loria P, Regulation of bile acid synthesis in humans: effect of treatment with bile acids, cholestyramine or simvastatin on cholesterol 7 alpha-hydroxylation rates in vivo. Hepatology 1991;14:830-7
   PubMed Web of Science ®Google Scholar